Furthermore, a recent retrospective study showed that treatment with Nivolumab plus Relatlimab could have a reduced efficacy in patients with type 2 diabetes, possibly due to a low expression of LAG-3 in tumor tissue [218]. Here, LAG3 is linked to neoplasm.